Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Open Label Study to Confirm the Diagnostic Potential of Intravenously Administered [15-O]-H2O to Identify Coronary Artery Disease During Pharmacological Stress and Resting Conditions Using PET Imaging (RAPID-WATER-FLOW)
This a Phase 3, prospective, open-label, multicenter study of \[15-O\]-H2O injection for PET imaging of subjects with suspected CAD. Approximately 182 evaluable participants with suspected CAD referred for testing will be included in the study at approximately 10 study sites in the United States and Europe. Approximately 215 participants will be enrolled to account for an estimated 15% drop-out rate. Screening assessments will occur prior to enrollment to confirm eligibility. All participants will receive two doses of \[15-O\]-H2O as part of a single PET imaging session (one dose at rest and one during pharmacological stress with adenosine). A safety follow-up phone call will occur 24 ± 8 hrs after completion of the \[15-O\]-H2O scan.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
University of Iowa
Iowa City, Iowa, United States
BAMF Healthcare
Grand Rapids, Michigan, United States
Mayo Clinic
Rochester, Minnesota, United States
Washington University
St Louis, Missouri, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
UT Southwestern Medical Center
Dallas, Texas, United States
University of Virginia Medical Center
Charlottesville, Virginia, United States
University of Ottawa Heart Institute
Ottawa, Ontario, Canada
Aarhus University Hospital
Aarhus, Denmark
University Hospital Freiburg, Clinic for Nuclear Medicine
Freiburg im Breisgau, Germany
Start Date
May 8, 2022
Primary Completion Date
April 30, 2026
Completion Date
December 31, 2026
Last Updated
February 5, 2026
215
ESTIMATED participants
[O-15]-Water PET Myocardial Perfusion Imaging (MPI)
DRUG
Lead Sponsor
MedTrace Pharma A/S
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT01311323